Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kewaunee Scientific Reports Results for Third Quarter

KEQU

STATESVILLE, N.C., March 4, 2014 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported sales and earnings for its third quarter ended January 31, 2014.

Net earnings for the quarter were $604,000, or $0.22 per diluted share, as compared to net earnings of $544,000, or $0.21 per diluted share, in the third quarter last year. Earnings for the quarter benefited from lower operating costs.

Sales for the quarter were $26,013,000, a decline of 5% from sales of $27,450,000 in the third quarter last year. Domestic sales were $21,544,000, up 5% from sales of $20,445,000 in the third quarter last year. Sales for the quarter benefited from the shipment of several large domestic orders received by the Company in earlier periods. The domestic laboratory construction marketplace continued to be challenging during the quarter, as fewer project opportunities were available of all sizes, public and private. International sales were $4,469,000, a decline of 36% from unusually strong sales of $7,005,000 in the third quarter last year. However, incoming international orders were well above the third quarter last year, as the Company successfully took advantage of a growing number of project opportunities in Asia and the Middle East.

The order backlog was $69.8 million at January 31, 2014, up slightly from $69.5 million at October 31, 2013, and down from $84.5 million at January 31, 2013. International orders in the backlog increased during the quarter, offsetting a decline in domestic orders. The order backlog is expected to increase in the fourth quarter of the current fiscal year, as the Company was recently notified of a large international contract award.

Net earnings for the nine months ended January 31, 2014 were $2,916,000, or $1.11 per diluted share, as compared to net earnings of $1,827,000, or $0.71 per diluted share, in the comparable period last year. Earnings in the current year benefited from a favorable product mix and lower operating costs.

Sales for the nine months ended January 31, 2014 were $84,114,000, a decline of 1% from sales of $85,318,000 in the comparable period last year. Domestic sales for the nine months ended January 31, 2014 were $70,678,000, an increase of 3% from sales of $68,757,000 in the comparable period last year.  International sales were $13,436,000, a decline of 19% from sales of $16,561,000 in the comparable period last year.

Cash on hand was $7.3 million at the end of the quarter, as compared to $4.9 million at the end of the same period last year. Short-term borrowings under the Company's bank line of credit were $3.9 million, as compared to $2.4 million at the end of the same period last year, and long-term debt was $4.7 million, as compared to $3.5 million. The debt-to-equity ratio was .28-to-1, as compared to .20-to-1 at the end of the same period last year. Working capital was $25.5 million, as compared to $24.3 million at the end of the same period last year.

"We continued to make excellent progress during the quarter," said David M. Rausch, Kewaunee's Chief Executive Officer. "I am pleased with sales and earnings, particularly since the third quarter is historically our slowest due to normal construction cycles and the large number of holidays. Also, we continued to make good progress in the quarter against our goals to strengthen the Kewaunee brand, strengthen relationships with existing customers, build relationships with new and prospective customers, reduce costs, and increase market share.

"Our Associates in Statesville did an excellent job controlling manufacturing and operating costs during the quarter. These lower costs are allowing us to continue to be very competitive in the domestic marketplace where fewer new projects available have intensified pressure on project selling prices. Our international team also made excellent progress during the quarter in winning projects, expanding and strengthening the Kewaunee sales organization, and strengthening the Kewaunee brand name globally.

"Looking forward, we expect that the financial results for the fourth quarter will likely be in line with, or slightly better than, the past two quarters."

Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, storage systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.

The Company's corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets.  One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific's website is located at http://www.kewaunee.com.

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Additional information concerning these and other factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Kewaunee Scientific Corporation

Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)














Three months ended


Nine months ended




 January 31,


 January 31,




2014


2013


2014


2013

Net sales



$    26,013


$    27,450


$    84,114


$    85,318

Cost of products sold


21,302


22,441


67,934


69,839

Gross profit



4,711


5,009


16,180


15,479

Operating expenses


3,773


4,054


11,676


12,205

Operating earnings


938


955


4,504


3,274

Other income


95


84


265


260

Interest expense


(116)


(80)


(276)


(295)

Earnings before income taxes


917


959


4,493


3,239

Income tax expense


292


177


1,505


962

Net earnings



625


782


2,988


2,277

Less: net earnings attributable to









    the noncontrolling interest


21


238


72


450

Net earnings attributable to 









    Kewaunee Scientific Corporation


$         604


$         544


$      2,916


$      1,827











Net earnings per share attributable to









    Kewaunee Scientific Corporation stockholders







       Basic



$        0.23


$        0.21


$        1.12


$        0.71

       Diluted



$        0.22


$        0.21


$        1.11


$        0.71











Weighted average number of common









shares outstanding









       Basic



2,615


2,590


2,606


2,586

       Diluted



2,645


2,604


2,627


2,596

 

 

Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

(in thousands)














 January 31,


April 30,






2014


2013

Assets





(Unaudited)



Cash and cash equivalents




$      6,658


$      5,811

Restricted Cash




677


691

Receivables, less allowances




21,970


25,884

Inventories





12,507


13,203

Prepaid expenses and other current assets




1,611


1,641

    Total Current Assets




43,423


47,230

Net property, plant and equipment




14,866


15,098

Other assets





6,674


6,414

Total Assets





$    64,963


$    68,742









Liabilities and Equity







Short-term borrowings and interest rate swap




$      4,169


$      6,997

Current portion of long-term debt




421


200

Accounts payable




8,926


10,406

Other current liabilities




4,435


4,512

    Total Current Liabilities




17,951


22,115

Other non-current liabilities




15,159


12,934

    Total Liabilities




33,110


35,049

Noncontrolling interest




220


2,017

Kewaunee Scientific Corporation equity




31,633


31,676

    Total Equity




31,853


33,693

Total Liabilities and Equity




$    64,963


$    68,742

 

 

Contact:

D. Michael Parker


704/871-3290

SOURCE Kewaunee Scientific Corporation